These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 5289712)

  • 1. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.
    Ho DH; Frei E
    Clin Pharmacol Ther; 1971; 12(6):944-54. PubMed ID: 5289712
    [No Abstract]   [Full Text] [Related]  

  • 2. Distribution and excretion of cyclocytidine in monkeys, dogs, and rats.
    Hirayama H; Sugihara T; Hamada F; Kanai T; Hikita J
    Gan; 1974 Apr; 65(2):153-61. PubMed ID: 4209835
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacologic studies of tritiated cytosine arabinoside (NSC-63878) in children.
    Finklestein JZ; Scher J; Karon M
    Cancer Chemother Rep; 1970 Feb; 54(1):35-9. PubMed ID: 5538163
    [No Abstract]   [Full Text] [Related]  

  • 4. Biochemical and pharmacologic studies with 1- -D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614), a depot form of cytarabine.
    Neil GL; Buskirk HH; Moxley TE; Manak RC; Kuentzel SL; Bhuyan BK
    Biochem Pharmacol; 1971 Dec; 20(12):3295-308. PubMed ID: 5002403
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL; Moxley TE; Manak RC
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral and parenteral activity of 2,2'-anhydro-1- -D-arabinofuranosyl-5-fluorocytosine against both intraperitoneally and intracerebrally inoculated mouse leukemia.
    Fox JJ; Falco EA; Wempen I; Pomeroy D; Dowling MD; Burchenal JH
    Cancer Res; 1972 Oct; 32(10):2269-72. PubMed ID: 4673145
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans.
    Wan SH; Huffman DH; Azarnoff DL; Hoogstraten B; Larsen WE
    Cancer Res; 1974 Feb; 34(2):392-7. PubMed ID: 4521089
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma half-life of cytosine arabinoside in patients with leukaemia--the effect of uridine.
    Baguley BC; Falkenhaug EM
    Eur J Cancer (1965); 1975 Jan; 11(1):43-9. PubMed ID: 1055682
    [No Abstract]   [Full Text] [Related]  

  • 9. ACTIVITY OF SELECTED COMPOUNDS IN SUBLINE OF LEUKEMIA L1210 RESISTANT TO CYTOSINE ARABINOSIDE (NSC-63878).
    WODINSKY I; KENSLER CJ
    Cancer Chemother Rep; 1964 Dec; 43():1-3. PubMed ID: 14250647
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential analysis of cyclocytidine, 1-beta-D-arabinofuranosylcytosine, and 1-beta-D-arabinofuranosyluracil by ultraviolet spectophotometry.
    Furner RL; Gaston RW; Strobel JD; el-Dareer S; Mellett LB
    J Natl Cancer Inst; 1974 May; 52(5):1521-8. PubMed ID: 4208713
    [No Abstract]   [Full Text] [Related]  

  • 11. Nucleosides. 48. Synthesis of 1-(5-deoxy-beta-D-arabinosyl)cytosine and related compounds.
    Falco EA; Fox JJ
    J Med Chem; 1968 Jan; 11(1):148-51. PubMed ID: 5637160
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical and pharmacological studies with 1-beta-D-arabinofuranosylcytosine in man.
    Creasey WA; Papac RJ; Markiw ME; Calabresi P; Welch AD
    Biochem Pharmacol; 1966 Oct; 15(10):1417-28. PubMed ID: 4291357
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro-in vivo correlation of drug metabolism--deamination of 1- -D-arabinofuranosylcytosine.
    Dedrick RL; Forrester DD; Ho DH
    Biochem Pharmacol; 1972 Jan; 21(1):1-16. PubMed ID: 4500983
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
    Schwendener RA; Schott H
    J Cancer Res Clin Oncol; 1996; 122(12):723-6. PubMed ID: 8954169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine.
    Dexter DL; Wolberg WH; Ansfield FJ; Helson L; Heidelberger C
    Cancer Res; 1972 Feb; 32(2):247-53. PubMed ID: 4333494
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparative study of the antitumor and antiviral activity of 1-beta-D-arabinofuranosyl-5-fluorocytosine (FCA) and 1-beta-D-arabinofuranosylcytosine (CA).
    Prince HN; Grunberg E; Buck M; Cleeland R
    Proc Soc Exp Biol Med; 1969 Apr; 130(4):1080-6. PubMed ID: 4305347
    [No Abstract]   [Full Text] [Related]  

  • 17. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy.
    Skipper HE; Perry S
    Cancer Res; 1970 Jun; 30(6):1883-97. PubMed ID: 4917694
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo.
    Young RC; Goldberg D; Schein PS
    Biochem Pharmacol; 1973 Jan; 22(2):277-80. PubMed ID: 4763256
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
    Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.